Drug
Ravulizumab
Ravulizumab: highest development phase Phase 3, developed by Alexion, Regeneron. 11 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alexion, Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ravulizumab NCT04248465 | Phase 3 | Amyotrophic Lateral Sclerosis |
| Ravulizumab NCT07024563 | Phase 3 | IgAN |
| Ravulizumab NCT04543591 | Phase 3 | Thrombotic Microangiopathy |
| Ravulizumab NCT07596784 | Phase 3 | Generalized Myasthenia Gravis |
| Ravulizumab NCT04557735 | Phase 3 | Thrombotic Microangiopathy |
| Ravulizumab NCT06291376 | Phase 3 | Immunoglobulin A Nephropathy |
| Ravulizumab NCT05746559 | Phase 3 | Chronic Kidney Disease |
| Ravulizumab NCT05133531 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| Ravulizumab NCT07557420 | Phase 3 | NMOSD |
| Ravulizumab NCT05346354 | Phase 2/3 | Neuromyelitis Optica Spectrum Disorder |
| Ravulizumab NCT05396742 | Phase 1 | Healthy |
Latest
No recent events.
Follow Ravulizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.